Journal Article

Human Herpesvirus 8: Current Issues

Michael J. Cannon, A. Scott Laney and Philip E. Pellett

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 37, issue 1, pages 82-87
Published in print July 2003 | ISSN: 1058-4838
Published online July 2003 | e-ISSN: 1537-6591 | DOI:
Human Herpesvirus 8: Current Issues

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


Although human herpesvirus 8 (HHV-8) is the etiologic agent of Kaposi sarcoma (KS), there are no formal guidelines for the clinical management of HHV-8 infection. In patients infected with human immunodeficiency virus (HIV), highly active antiretroviral therapy (HAART) is the best tool for the prevention of KS. In patients who have undergone transplantation, KS is often managed by curtailing immunosuppressive therapies, despite the potential adverse consequences for graft survival. Interventions related to HHV-8 infection might improve the management of KS in immunocompromised patients. However, knowledge from HHV-8 research cannot yet be translated into clinically useful interventions. Achieving clinical utility will require the commercial development of diagnostic tools currently available only in research settings and the evaluation of potential interventions. Such interventions might include the use of HHV-8 diagnostics to identify patients at high risk and to aid in the early detection of KS, prophylaxis with antiherpes drugs to prevent KS, treatment of KS with antiherpes drugs, and donor/recipient screening for organ transplantation.

Journal Article.  3505 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.